Release date: 2014-07-28 A few centimeters of the mouth in the patient's body, bleeding less than 100 ml, can successfully complete a minimally invasive heart surgery within two hours, and is completed under the premise of the heart. This was enough to be an incredible miracle a few years ago, but it has become a reality in today's high-tech. It is the robot technology that allows doctors to break through the limitations of the human eye. Through robotic surgery, the patient's trauma can be minimized, and the precision of surgery is also raised to a new level. As a leader in assisted medical robots for abdominal surgery, Intuitive Surgical (NASDAQ: ISRG) is the world's most advanced medical robot, the manufacturer of the da Vinci Surgical System. . As the earnings report released after the market on the 22nd exceeded market expectations, the intuition surgery company surged 17.7% to $461.63 on the 23rd, the largest increase in the S&P 500 index on that day. Since its inception in 2000, Intuition Surgery has been the darling of Wall Street institutions, and its share price has risen more than 70 times in more than a decade. Market optimistic about new product sales The second quarter earnings report released by Intuition Surgery on the 22nd showed that the company's quarterly profit fell to $104 million ($2.77 per share) from $159.1 million ($3.9 per share) a year ago. The company's quarterly revenue fell 11% year-on-year to $512.2 million, better than market expectations of $499 million. In the second quarter, the Insect Surgery's star product DaVinci system shipped 96 units, which was less than the 143 units in the same period last year, but better than the 87 units in the first quarter. Market participants also noted that 50 of the 96 Da Vinci systems shipped in the second quarter were the latest four generations (da Vinci Xi), which just received the US Food and Drug Administration (FDA) in April this year. Recognition. After the release of the earnings report, Wall Street institutions have raised the investment rating of the Intuition Surgery Company. Raymond James analysts said the new product will make the intuitive surgery company's long-term prospects better, upgrade its rating to "out of the market" and raise the target price to $500. Stifel analysts believe that under the new products, Intuition Surgery will maintain a sales growth rate of more than 10% in the next 3-5 years, and the profit growth rate will reach 15%-20%, and its rating will be upgraded to “ Buy" and raise the target price to $600. Star products continue to change As a medical robot that assists complex surgery in a minimally invasive manner, the Da Vinci system was officially approved by the US FDA in 2000. Originally used for minimally invasive surgery in urology, this surgical system is now being used more and more in surgical minimally invasive surgery such as cardiac surgery, and is being used by hospitals around the world. The Da Vinci system is mainly composed of three parts: one is the surgeon's operation console; the other is the three-dimensional imaging video imaging platform; the third is the robotic arm, the camera arm and the surgical instrument to form a mobile platform. During the operation, the surgeon passes the three-dimensional vision system and the motion calibration system to control the operation, and the mechanical arm and the surgical instrument simulate the medical movement and operation of the doctor. The third generation of products (da Vinci Si) is commonly used on the market. According to industry insiders, the system is already in place in real-time operation, but there are still limitations in the scope of operation. In the fourth generation, intuition surgery companies have made a number of improvements to the Da Vinci system. According to industry analysts, the fourth feature of the fourth generation is the design of four minimally invasive scalpels with a rotatable mount that can be rotated to any part of the body. If the surgeon thinks it is necessary, the four minimally invasive scalpels can be removed and re-implanted inside the body. In addition, the fourth-generation product can be used with the Insect Surgery's Firefly Fluorescence Imaging System to provide doctors with more real-time visual information, including vascular testing, bile ducts, and tissue perfusion. The product is highly scalable and provides a seamless connection to other imaging and instrumentation technologies. Intuition Surgery's revenue is mainly derived from the sales of Da Vinci systems and accessories and service fees. The Da Vinci system is priced between $1 million and $2 million, and the average annual service cost per system after sale is $100,000. According to industry insiders, the business model of the Intuitive Surgery Company is a typical “razor and blade†model. The sales of accessories and service fees after the company’s sales increase is greater than the revenue growth of the Da Vinci system itself. An important reason that Wall Street respects. This year's stock price fluctuations Since its launch in 2000, Wall Street institutions have been admiring the intuitive surgery company. They believe that the medical robot industry has a bright future, and the entry threshold is high, and the high threshold represents high profitability. On the one hand, the development of medical robots requires strong capital and cutting-edge technology to make reserves; in addition, medical robots need to be strictly tested and evaluated by the regulatory authorities before mass production, and the company's first-mover advantage is very obvious. Since April 2001, the stock market of Intuition Surgery has gone out of the big bull market for more than 10 years. The stock price started from less than 8 US dollars. In April 2012, it rose to a record high of nearly 586 US dollars, the biggest increase of more than 70 times. However, the volatility of the stock market of intuition surgery companies has increased since this year. On December 31 last year, the stock closed at $384, and it was once raised to $540 in early April. Since then, the stock price has fallen sharply. After the initial low of 352 US dollars in May, the stock price continued to rebound to more than 400 US dollars. Intuition Surgery currently has a market capitalization of more than $17 billion and a P/E ratio of 38 times. Market participants said that because the company is currently focused on producing a medical robotic system, the market has given the company a market value of nearly $20 billion at a "reasonable" level. If the company can develop or expand the robot business in other medical fields, the stock price still has upside potential. However, it is worth noting that with the gradual saturation of the US market, if the intuitive surgery company can not vigorously develop other markets, the company will only rely on the maintenance of the stock market in the future, and the company's profit growth will be slowed down. At the investor conference after the release of the latest earnings report, the Intuitive Surgery Company said it will strengthen its construction in Europe and Japan. At the same time, the company will increase the promotion of the fourth generation of Da Vinci system products. At present, the market feedback on new products is “very positiveâ€. Source: China Gold Online (Beijing)
Our factory majors in producing Single Port,Double Port and Small Port for infusion bag and bottle in clinical pharmaceutical packaging. The port is used to connect the combined top cap with the infusion bag or bottle .The joint is produced in a clean plant which reaches to 100000-100 million class grade cleanliness .We will have a professional testing for the materials we use before starting production, only when it is proved to be qualified, we will go to the next phase. During the productive process, we will choose some samples from the cargo from time to time to check the quality. For more details , pls feel free to contact us.
Pp Port,Pp Ship Port,Single Fiber Port,Universal Port SUZHOU CRH PHARMACEUTICAL TECHNOLOGY CO.,LTD , https://www.crh-health.com